67 results about "Nerve conduction velocity" patented technology

Embodiments of the invention relate to a wireless physiological monitoring system. The system includes at least one wireless sensor and a monitoring device which are linked to one another of a wireless fashion for measuring physiological signals of a patient. The at least one wireless sensor is located on the patient and may comprise a wireless surface electrode assembly or a wireless needle assembly. The system may also comprise a wireless stimulator syncronized with the wireless sensor for performing certain diagnostic tests, such as nerve conduction velocity tests, for example. The wireless sensor preferably includes active, reference and common conductors. The common conductor can be used to measure the common mode voltage of the patient in the vicinity of the testing, and this voltage can then be subtracted from the measured active and reference voltages.

Methods and process for detection of myocardial ischemia involve detection and analysis of changes in electrical conduction velocity within the heart to monitor changes in the condition of the cardiac muscle and indicate possible ischemia. Conduction velocity slows considerably when oxygen supply to the heart is reduced. Analysis of electrical conduction velocity can be used to verify the occurrence of myocardial ischemia in a more reliable manner. Changes in conduction velocity may be monitored based on conduction time between electrodes positioned in the left and right ventricles of the heart. The electrodes may be endocardial or epicardial electrodes. In general, the techniques may involve launching a stimulation waveform at one electrode and sensing a local cardiac depolarization at another electrode to assess conduction time.

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT₂) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT₂ receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

A method of selectively blocking a portion of a nerve signal is disclosed. The method may include the step of providing an electrode around a subject's peripheral nerve and connecting the electrode to a stimulator. The stimulator may then energize the electrode with a continuous periodic waveform of at least 50 kHz. This energization of the electrode can result in the selective block of one of: 1) a fast portion of a nerve signal having a conduction velocity greater than 2 m/s, and 2) a slow portion of the nerve signal having a conduction velocity less than 2 m/s. A method according to the present disclosure may allow the non-blocked portion of the nerve signal to be conducted substantially unimpeded.

The invention provides an application of a pyrroloquinoline quinone (PQQ) active substance in preparation of medicaments for treating and/or improving a diabetic complication, namely diabetic foot and further provides a health-care product composition or a pharmaceutical composition containing pyrroloquinoline quinone. The active substance, namely the pyrroloquinoline quinone in the composition provided by the invention has significant treatment and/improvement action against the diabetic complication, namely the diabetic foot by improving nerve conduction velocity, reducing sorbitol content, increasing the open number of capillaries, reducing whole blood viscosity, enhancing blood flow, increasing neural blood flow, promoting blood circulation, improving microcirculation of blood vessels and reducing gangrene ulcers of the foot. Therefore, the pyrroloquinoline quinone has great application prospects in prevention, treatment and/or improvement of occurrence and development of the diabetic complication, namely the diabetic foot.

The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT₂) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT₂ receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

A device for measuring sural nerve conduction velocity and amplitude, the device comprising:

• • a housing;
  • stimulation means mounted to the housing for electrically stimulating a human sural nerve;
  • a biosensor releasably mounted to the housing, the biosensor comprising a plurality of electrodes for detecting a sural nerve response evoked by the stimulation means;
  • acquisition means mounted to the housing and electrically connected to the biosensor for electrically acquiring the sural nerve response detected by the biosensor;
  • detection means mounted to the housing and electrically connected to the stimulation means and the acquisition means for detecting shorting or shunt of the stimulation current on the surface of the skin;
  • processing means mounted to the housing and electrically connected to the acquisition means for digitizing, processing and storing the acquired sural nerve response;
  • calculation means mounted to the housing and electrically connected to the processing means for calculating the conduction velocity and amplitude of the processed sural nerve response; and
  • display means mounted to the housing for displaying the sural nerve conduction velocity and amplitude;
  • wherein the stimulation means and the biosensor are designed to be placed on a patient's anatomy, in the vicinity of a sural nerve, by manipulating the housing.

The invention discloses a diabetic peripheral neuropathy treatment medicine and a manufacturing method thereof. The medicine is mainly prepared from radix astragali, radix rehmanniae, rhizoma dioscoreae, angelica sinensis, cornus officinalis, cassia twig, salvia miltiorrhiza, lumbricus and leech. The medicine has efficacies of Qi tonifying, Yin nourishing, kidney tonifying, blood circulation promoting, stasis removing and meridian activating and has functions of reducing blood glucose, increasing microvascular diameter and blood flow volume, increasing sciatic nerve conduction velocity and increasing sural nerve tract area, myelin sheath fiber number and myelin sheath fiber density. The medicine can be used for treatment of diabetic peripheral neuropathy and has advantages of remarkable curative effects, quick action, short treatment period, safety and avoidance of relapse and side effects.

The exemplified systems and methods facilitate a nerve conduction block at a target nerve using electrical stimulation applied from one or more electrodes located on a percutaneous lead that are placed in parallel, or substantially in parallel, and without direct contact, to a long axis of the peripheral nerve over an overlapping nerve region of greater than about 3 millimeters. The exemplified system and method can be further configured to block nerve condition without eliciting onset activity and co-excitation of non-targeted structures. The exemplified method and system can be performed using conventional percutaneous leads, though an improved percutaneous lead design is disclosed herein. In an aspect, an introducer is disclosed that facilitates accurate and consistent insertion of the percutaneous lead to the specified or intended position relative to the target nerve. In another aspect, a treatment kit comprising the various system components to treat pain is disclosed.

The invention provides a pharmaceutical composition for treating or preventing nerve damage. The pharmaceutical composition comprises the following components: asiaticoside, an Aloe vera extract, a sweetsop seed extract, a leontopodium alpinum extract, and a vascular endothelial growth factor (VEGF). The pharmaceutical composition of the invention is useful for inducing neurite outgrowth, for promoting stem cell function, and/or for promoting functional recovery and enhancing synapse formation and synaptic plasticity in damaged and/or injured neurons in acute and chronic injury, and can significantly alleviate impaired sciatic nerve function, increase nerve conduction velocity, increase axon count, and repair axons. Clinical studies show that the pharmaceutical composition of the inventioncan improve muscle strength, accelerate repair of damaged nerve tissue, and improve nerve tissue transmission and metabolic disorders in patients with peripheral nerve injury.

A consideration of electromagnetic energy transfer following from Poynting's theorem leads to a power signal that facilitates the detection of biomedical pulses. This power signal is derived from and is complementary to the measured biomedical voltage signals. The method may be applied to F-wave signals obtained from nerve conduction studies as well as other biomedical signals. Among other things, this power signal is useful in latency determination.

The exemplified systems and methods facilitate a nerve conduction block at a target nerve using electrical stimulation applied from one or more electrodes located on a percutaneous lead that are placed in parallel, or substantially in parallel, and without direct contact, to a long axis of the peripheral nerve over an overlapping nerve region of greater than about 3 millimeters. The exemplified system and method can be further configured to block nerve condition without eliciting onset activity and co-excitation of non-targeted structures. The exemplified method and system can be performed using conventional percutaneous leads, though an improved percutaneous lead design is disclosed herein. In an aspect, an introducer is disclosed that facilitates accurate and consistent insertion of the percutaneous lead to the specified or intended position relative to the target nerve. In another aspect, a treatment kit comprising the various system components to treat pain is disclosed.

The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT₂) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT₂ receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

The invention belongs to the technical field of a traditional Chinese medicine, and particularly relates to a medicine for treating diabetic peripheral neuropathy, a preparation method thereof and usethereof. The medicine for treating diabetic peripheral neuropathy is obtained by combining a mixed extract of a cassia seed water extract and a cassia ethanol extract with an extraction part containing an anthraquinone compound, unsaturated fatty acid, and a naphthoppyrone component. The medicine can improve peripheral nerves by increasing nerve conduction velocity and improving local microcirculation, and thus can play a role in preventing and treating the diabetic peripheral neuropathy.

The invention discloses a brain-controlled rehabilitation system motion imagery recognition system integrating a complex network and graph convolution. According to the system, a testee carries out motion imagery through watching a hand fist clenching and stretching motion video, and the motor imagery EEG signals of the testee is collected through an EEG signal collection device; a motion intention recognition module is used for constructing a multi-entropy complex network for the obtained motion imagery EEG signals; the characteristics in the aspects of symbol fluctuation, frequency energy distribution and amplitude fluctuation in the motion imagery EEG signals are extracted; and the characteristics are input into a graph convolutional neural network to classify and identify fist clenching motion imagery EEG signals and hand stretching motion imagery EEG signals, and a classification result is transmitted to a brain-controlled rehabilitation system to prompt the testee to execute handfist clenching and stretching actions. According to the brain-controlled rehabilitation system, a closed-loop path is formed between motion intention and limb feeling, the muscle strength and the nerve conduction speed of a testee are gradually enhanced, recovery of a damaged brain movement area is promoted, and the movement capacity is gradually recovered.